Attached files
| file | filename |
|---|---|
| 10-K - 10-K - IMMUNIC, INC. | vtl-123117x10k.htm |
| EX-32.2 - EXHIBIT 32.2 - IMMUNIC, INC. | vtl-123117xexhibit322.htm |
| EX-32.1 - EXHIBIT 32.1 - IMMUNIC, INC. | vtl-123117xexhibit321.htm |
| EX-31.2 - EXHIBIT 31.2 - IMMUNIC, INC. | vtl-123117xexhibit312.htm |
| EX-31.1 - EXHIBIT 31.1 - IMMUNIC, INC. | vtl-123117xexhibit311.htm |
| EX-21.1 - EXHIBIT 21.1 - IMMUNIC, INC. | vtl-123117xexhibit211.htm |
| EX-10.13 - EXHIBIT 10.13 - IMMUNIC, INC. | a1013_ukglobalstockoptiona.htm |
| EX-10.10 - EXHIBIT 10.10 - IMMUNIC, INC. | a1010_vitaltherapiesxexecu.htm |
| EX-10.4 - EXHIBIT 10.4 - IMMUNIC, INC. | a104_transitionagreementtw.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statement on S-3 (No. 333-204097) and Registration Statements on Form S-8 (Nos. 333-196571, 333-204644 and 333-211539) of Vital Therapies, Inc. of our report dated March 13, 2018 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP |
San Diego, California |
March 13, 2018 |